Cargando…
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Short interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are the most clinically advanced oligonucleotide-based platforms. A number of N-acetylgalactosamine (GalNAc)-conjugated siRNAs (GalNAc-siRNAs), also referred to as RNA interference (RNAi) therapeutics, are currently in various sta...
Autores principales: | Janas, Maja M., Harbison, Carole E., Perry, Victoria K., Carito, Brenda, Sutherland, Jessica E., Vaishnaw, Akshay K., Keirstead, Natalie D., Warner, Garvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249674/ https://www.ncbi.nlm.nih.gov/pubmed/30139307 http://dx.doi.org/10.1177/0192623318792537 |
Ejemplares similares
-
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018) -
Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
por: Sutherland, Jessica E., et al.
Publicado: (2020) -
Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs
por: Agarwal, Saket, et al.
Publicado: (2021) -
Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011) -
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)